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This review analyzes the  available literature on the impact of intermittent fasting (IF), a
nutritional intervention, on different aspects of metabolism. The epidemic of metabolic
disturbances,  such as  obesity, metabolic syndrome (MS), and diabetes mellitus type 2  has
led  to  an increase in the prevalence of cardiovascular diseases, and affected patients might
signiﬁcantly  beneﬁt from modiﬁcations in nutritional habits. Recent experimental stud-
ies have elucidated some of the  metabolic mechanisms involved with IF. Animal models
have  shown positive changes in glucose (lower plasma glucose and insulin levels) and in
lipid  metabolism (reduced visceral fat tissue and increased plasma adiponectin level), and
an  increased resistance to stress. Despite the  limited number of samples studied, positive
results  have been reported on the  impact of IF for human health. IF is reported to improve the
lipid  proﬁle; to decrease inﬂammatory responses, reﬂected by changes in serum adipokine
levels;  and to change the expression of genes related to inﬂammatory response and other
factors.  Studies on obese individuals have shown that patient compliance was greater for
IF  than other traditional nutritional approaches (calorie restriction), and IF was found to be
associated  with low oxidative stress. Recent reports suggest that IF exerts a  positive impact
on  the  metabolic derangements commonly associated with cardiovascular diseases, and
that  it  may be a  viable and accessible intervention for most individuals. Therefore, further
clinical  studies are  essential to test the effectiveness of IF in preventing and controlling
metabolic  and cardiovascular diseases.
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Esta revisão traz uma análise de dados disponíveis na literatura sobre o  impacto do
jejum  intermitente, uma modalidade de intervenc¸ão  nutricional, em diferentes aspectos
do  metabolismo. A  epidemia de anormalidades metabólicas, como obesidade, síndrome
metabólica  e diabetes mellitus tipo 2, tem ocasionado um aumento na prevalência de
doenc¸as  cardiovasculares, condic¸ões  em que os indivíduos afetados apresentam impor-
tantes  melhorias advindas de modiﬁcac¸ão  nos hábitos alimentares. Estudos experimentais
recentes  têm elucidado a modulac¸ão  do metabolismo por jejum intermitente. Testes com
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animais têm mostrado alterac¸ões  positivas no metabolismo glicídico (valores menores de
glicemia e insulinemia) e lipídico (reduc¸ão  no volume de gordura visceral e aumento nos
valores de  adiponectina plasmática), além de  uma maior resistência ao estresse. Apesar dos
estudos disponíveis apresentarem populac¸ões  muito reduzidas, observaram-se resultados
positivos com esta intervenc¸ão  também na saúde humana. Os resultados indicam mel-
horias no perﬁl lipídico, reduc¸ão  de respostas inﬂamatórias, com reduc¸ão  na liberac¸ão  de
adipocinas inﬂamatórias e alterac¸ões  na expressão de genes relacionados com a  resposta
inﬂamatória e de outros fatores. Em  indivíduos obesos observou-se uma melhor adesão
ao jejum intermitente em relac¸ão  a intervenc¸ões  tradicionais (restric¸ão  calórica), além
da reduc¸ão  no estresse oxidativo desta populac¸ão.  Dessa maneira, por se tratar de  uma
intervenc¸ão  viável e acessível para a maioria dos indivíduos, novos estudos clínicos são
necessários para testar a eﬁcácia desta intervenc¸ão  na  prevenc¸ão  e  no controle de  doenc¸as
metabólicas  e  cardiovasculares.
Introduction
The human genotype is  believed to have evolved from
600,000  BC to 25,000 BC, when humans were hunter-
gatherers.1 During this period, major energy oscillations
appear to  have selected genes that regulate metabolism for
efﬁcient  nutrient usage and increased fat storage, which rep-
resents  an evolutionary beneﬁt consistent with the thrifty
genotype  theory proposed by James V.  Neel.2 While the  envi-
ronment  changed drastically with urbanization and easy
availability of food, the genotype remains largely unaltered.
This  imbalance has  resulted in  an epidemic of conditions
characterized by metabolic disturbances, such as  obesity,
metabolic syndrome (MS), and diabetes mellitus type 2
(DM2).1,3,4
While obesity is easily deﬁned by body composition (body
mass  index [BMI] > 30 kg/m2), and DM2  by elevated blood
glucose levels, MS  is  recognized by a cluster of metabolic
markers whose importance and contribution have greatly
changed  over time. Despite this difference, the three condi-
tions  have common pathophysiological backgrounds. Firstly,
all  these conditions involve insulin resistance, elevated levels
of  plasma lipids, and increased levels of chronic inﬂammatory
mediators. Secondly, the consequent metabolic proﬁle consid-
erably  increases cardiovascular risk. Finally, individuals with
any  of these conditions can beneﬁt from signiﬁcant lifestyle
changes.5–7 Notably, modiﬁcation of nutritional habits is now
considered extremely important for reducing cardiovascular
risk.8,9
Intermittent fasting (IF) is an  interventional strategy
wherein individuals are subjected to varying periods of fas-
ting.  IF has recently attracted attention because experimental
studies  have highlighted its potential for correcting metabolic
abnormalities.10 This regimen has also shown better adher-
ence  than other methods.11
This review analyzes existing data on the  impact of IF on
different  aspects of metabolism.
Methodology
Experimental studies and clinical trials on IF available in the
PubMed  database at the time of manuscript preparation were
reviewed.  Animal and human studies were searched for by
using  the key words “intermittent fasting,” “alternate day
fasting,”  and “starvation” either alone or combined with “car-
diovascular risk,” “obesity,” and “metabolic syndrome.”
The ﬁrst search retrieved over 22,000 results, mostly by
using  the keyword “starvation” alone (21,735). A detailed
search yielded 26 articles on the impact of fasting or IF on
metabolic parameters related to cardiovascular risk.
Pathophysiological  basis  of  obesity  and  MS
Obesity and MS were the main outcomes analyzed in the stud-
ies  on IF.
Adipose tissue is now known to  function as  an endocrine
organ involved in regulating metabolism, rather than a passive
reservoir  for energy storage.12 Adipocytes, mesenchymal cells,
and  inﬁltrating macrophages together produce cytokines and
adipokines  that have important regulatory effects on inﬂam-
mation,  insulin sensitivity, coagulation, vascular homeostasis,
appetite, energy expenditure, etc. When this production is
deregulated,  e.g., by excessive adipose tissue, the organ-
ism  appears to develop low-grade chronic inﬂammation,
leading to insulin resistance and cardiovascular disease.13
Adipocytes produce important proinﬂammatory adipokines,
such  as  leptin, tumor necrosis factor alpha (TNF-), resistin,
angiotensinogen, interleukin-6 (IL-6), and plasminogen acti-
vator  inhibitor-1 (PAI-1), as well as nonesteriﬁed fatty acids
and  C-reactive protein (CRP), which are  atherogenic.14,15
Certain adipokines have cardioprotective action, such
as  adiponectin, which is abundant in human circulation.
Adiponectin was  primarily investigated for its ability to pro-
mote  insulin sensitivity by suppressing gluconeogenesis and
increasing  fatty acid oxidation, which in turn reduce triglyc-
eride  accumulation in the liver.13,16 Moreover, adiponectin
regulates endothelial function by increasing the produc-
tion  of endothelial nitric oxide; by inhibiting endothelial
cell  activation and endothelium–leukocyte interaction; by
enhancing  phagocytosis; and by suppressing macrophage
activation, macrophage-to-foam cell transformation, and
platelet  aggregation.17–19
Adipokines might represent the evolutionary pathway that
led  excessively nourished humans to obesity, insulin resis-
tance,  MS, and cardiovascular disease. Indeed, obese patients
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with excess visceral fat show increased adipokine expression.
However, weight loss is related to reduced plasma levels of
metabolically  active substances.20
Effects  of  intermittent  fasting  on animal  models
Metabolic mechanisms triggered by IF were well elucidated by
recent experimental studies. Anson et  al.10 investigated glu-
cose  metabolism and enhanced neuronal resistance to  stress
in  C57BL/6 mice subjected to ad libitum diet, IF, or limited
daily food intake for 22 weeks. Neuronal stress was induced
at  the end of the 22nd week through an injection of kainate,
a  seizure- and neuronal damage-inducing exotoxin. The
IF  group showed signiﬁcantly lesser histopathological brain
changes,  and lower plasma glucose and insulin levels than the
others.  These ﬁndings were reproduced in male Wistar rats.21
Similarly, a  study on the lipid metabolism of male C57BL/6J
mice  subjected to alternate-day fasting (ADF) or alternate-
day  50% calorie restriction (ADCR 50%) showed a signiﬁcant
reduction in the size of adipocytes of both visceral and subcu-
taneous  fat.  The authors also found that IF causes oscillation
of  triglyceride metabolism between anabolism (gluconeoge-
nesis and de novo lipogenesis) and catabolism (lipolysis).22
The same group later reported that female C57BL/6J mice
subjected to four-week IF showed signiﬁcantly reduced vis-
ceral  fat percentage, increased subcutaneous fat percentage,
increased  plasma adiponectin levels, and unchanged amount
of  fat tissue.11
Mager  et al. investigated heart-rate variability in  12
Sprague-Dawley rats during 16 weeks of nutritional inter-
vention by using an implanted telemetric transistor.23 After
16  weeks, rats in  the IF group showed reduced sympathetic
activity associated with increased vagal tone. This reduc-
tion  might have immunomodulatory effects, which would
attenuate  the  release of proinﬂammatory substances, such
as  TNF-, IL-6, and IL-18.
Increased  resistance  to stress  after  intermittent
fasting
Resistance to stress might be a  reasonable basis for increased
resistance to  cardiovascular and endocrine diseases.
Wan  et  al. evaluated the response to  cardiovascular stress
in  male Wistar rats undergoing IF by using a telemetric transis-
tor,  and found that the rats showed rapid return to basal values
of  blood pressure and heart rate after induced cardiovascular
stress, and presented no alterations in the plasma levels of
stress  biomarkers, such as adrenocorticotropic hormone and
corticosterone, during stress.21 Further, analysis of heart-rate
variability demonstrated a better norepinephrine response to
stress, thereby indicating an  improved autonomic response in
the IF group versus the control group.
Wan et al. later reported that a diet supplemented with
2-deoxyglucose (2-DG) -  a  glycolytic inhibitor and metabolic
stressor - on alternate days could mimic  the effects of IF
in  Sprague-Dawley rats.24 They observed that both IF and
2-DG  supplementation were capable of reducing heart rate,
blood  pressure, and glucose levels to similar extents. The
authors  suggested that the mechanisms underlying the  pos-
itive  metabolic response to IF may  be attributed to the fact
that  periodic metabolic stress can induce adaptive changes
in  cardiovascular physiology and glucose metabolism that are
associated with a  “less atherogenic” proﬁle.
An alternative cardioprotective action of IF was  evaluated
by  Ahmet et al.; they maintained 30  Sprague-Dawley rats
under  IF for three months and a control group with normal
feeding.25 Thereafter, all animals were  submitted to coro-
nary  artery ligation to induce myocardial infarction (MI) or to
sham  surgery. The IF group showed lower left ventricular (LV)
mass,  lower LV wall thickness, and signiﬁcantly lesser ven-
tricular  remodeling than the control group. Notably, 23 hours
after  surgery, a signiﬁcantly reduced degree of apoptosis and
neutrophil  inﬁltration was noted in the IF group with MI,  pos-
sibly  contributing to  a smaller ventricular size. The authors
proposed that IF induces an ischemic preconditioning in the
cardiac  muscle that protects myocardial cells from ischemic
damage. Similar results were recently reported by Wan  et al. on
male Wistar rats.26 In this study, plasma adiponectin and IL-
6  concentrations were  measured, which showed an  increase
in  the former and a  decrease in the latter. The authors sug-
gested  that the observed beneﬁts of IF might be attributed to
increased  plasma adiponectin levels.
More recently, Katare et al., performed a  study on the
impact of IF started after MI induction and maintained for
six  weeks.27 The male Wistar rats subjected to IF showed
a  decrease in cardiomyocyte hypertrophy and ﬁbrosis area,
reduced  oxidative stress, better cardiac performance, and bet-
ter survival rates than the control group. The authors also
noted  an increased expression of the BDNF gene, responsible
for  the enhanced expression of vascular endothelial growth
factor  (VEGF) in  the cardiac muscle; this resulted in  increased
angiogenesis and decreased apoptosis.
In another experimental study, streptozotocin was  used to
induce  diabetes mellitus type 1 before diet intervention in
Sprague-Dawley rats.28 After eight weeks of IF,  the diabetic
IF  group showed blood pressure levels similar to those of the
non-diabetic  control group, indicating that glomerular dam-
ages  promoted by diabetes were somehow prevented. Other
ﬁndings  were normal blood levels of glucose, albumin, HDL-
C,  and blood urea nitrogen; increased resistance to oxidative
stress;  and reduced incidence and intensity of degenerative
structures in the  kidneys. Changes in  the expression of some
genes  involved with cellular survival (p53, p38, and Sir  2) were
also  demonstrated.
Studies evaluating the potential of IF in the recovery
from spinal cord injury have also shown intriguing results.
Plunet  et al. assessed the  effect of ADF in a  group of male
Sprague–Dawley rats after cervical spinal cord injury.29 The
intervention proved to be neuroprotective, with a  50% reduc-
tion  in lesion volume and increased sprouting of corticospinal
axons. The intervention also promoted plasticity; improved
behavioral recovery, evident by improved gait-pattern and
forelimb  function during ladder-crossing; and enhanced verti-
cal  exploration. Jeong et  al. investigated the effect of the same
dietetic  intervention, started before or after a different spinal
cord  lesion (thoracic contusion) in Sprague–Dawley rats.30
Both groups subjected to  the intervention (before or after
the  lesion), showed positive results, with a  better functional
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recovery, along with improvement of several parameters of
their  walking pattern. The prophylactic group (IF started
before  the lesion) performed slightly better than the thera-
peutic  group (IF started after the lesion). The results were  also
superior  in  beneﬁts when compared with a group of rats con-
suming  the same amount of calories as  the ADF group (25%
calorie  restriction) everyday. Davis et al. also found positive
results  assessing not only spinal cord lesion but also traumatic
brain  lesion (TBL) induced in Sprague–Dawley rats.31 They
found  that fasting for 24  hours after moderate TBL confers
neuroprotection, maintains cognitive function, and improves
mitochondrial function. The results conﬁrm the beneﬁcial
role  of this kind of calorie restriction in other organisms.
Metabolic  changes  during  fasting  in humans
Metabolic changes due to fasting in humans were ﬁrst investi-
gated  in the beginning of the century for treating obesity and
other  conditions, such as  seizure disorders.32–34
Kerndt et al. investigated the metabolic effects of long-term
fasting  in  human subjects who underwent a  36-day com-
plete  fasting regimen for religious reasons.35 They noted a
signiﬁcant decrease in blood pressure, reaching signiﬁcance
on  the 33rd day, accompanied by negative sodium balance.
Changes in metabolic fuel were observed soon after the fasting
period  started. Plasma glucose levels dropped immediately
at  the beginning of the studies and remained low through-
out  the fasting period. Lipolysis and ketogenesis increased,
gluconeogenesis remained higher than baseline levels, and
glycogenolysis was  reduced to undetectable levels.
Carlson et al. subjected healthy human volunteers to
60  hours of fasting and collected blood samples at 12 and
60  hours.36 They observed a  decrease in plasma glucose by
30%  and in insulin by 50%; a signiﬁcant increase in the extent
of  lipolysis and fat oxidation; and moderate increase in the
extent  proteolysis and protein oxidation. This increase of
fat  oxidation provides the substrate for gluconeogenesis and
compensates  for the decline in carbohydrate oxidation and
glycogenolysis, thus conﬁrming a switch of metabolic fuels.
ADF  is considered a  variation of complete fasting that is  easier
to  maintain for longer periods and has remarkable metabolic
beneﬁts.  Studies on healthy subjects demonstrated a  simi-
lar  adaptation of energetic substrates. This action was  also
conﬁrmed  by changes in  the muscular expression of genes,
such  as  GSK-3, which is responsible for the regulation of
glycogen  synthesis pathways, favoring glycogen reposition.37
IF also down-regulates mTOR expression in muscle tissue,
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another important gene responsible for the modulation of
nutrient  signaling, and could reﬂect lesser protein synthesis
and  increased expression of carnitine acyltransferase 1 (CPT-1)
in  muscle tissue, as  well as  an increase in fat oxidation.38,39
Results from these and other studies on similar popu-
lations have shown improvements in the lipid proﬁle, with
higher  HDL-cholesterol levels in women and lower triglyceride
levels  in men, and increased muscular expression of Sirt 1
(40)  −a gene involved with the regulation of food intake, fat
metabolism, cell differentiation, apoptosis, and prevention of
aging.35 In these studies, an  increase in stress resistance was
demonstrated after three weeks of intervention.40 A summary
of  the main ﬁndings is presented in Fig. 1.
Clinical  implications
The general health beneﬁts involved with intermittent fasting
in  humans still have not been fully explored in the litera-
ture.  Johnson et al. described this phenomena after studying
the  article by Vallejo, published in 1956 in a  Spanish scien-
tiﬁc  magazine. In his study of elderly subjects living in  a
nursing  home, Vallejo did  not change the overall calorie con-
sumption,  only the pattern of eating.41 The subjects would
alternate between ad libitum diet for one day, followed by a
very  restrictive diet on the next day. The results were quite
interesting, revealing an important increase in  the lifespan,
demonstrated by a  shorter number of days spent in  the inﬁr-
mary.  It is  important to emphasize that there was  no calorie
restriction involved in  this intervention, thus the results were
a  consequence of the meal pattern alterations. Johnson con-
cluded  that this was  probably just the tip of the iceberg, and
that  the health improvements derived from IF are probably
seen  in very different aspects of the organism, as observed in
other studies exploring different conditions.41
Some latter studies were designed to evaluate the conse-
quences of this intervention in speciﬁc health conditions. One
interesting  model analyzed consisted of individuals following
Ramadan.
Ramadan  is a  holy month in the Islamic calendar, in  which
Muslims  must refrain from eating or  drinking during daylight
hours,  thereby resulting in  approximately 12 hours of fasting.
These  features make Ramadan a natural model to  study IF
in  humans. Aksungar assessed cardiovascular health in  Mus-
lim  individuals during Ramadan, with special emphasis on
coagulation.42 The results showed improvements in the lipid
proﬁle,  with increased HDL-cholesterol levels and decreased
values of HDL risk factor (CT/HDL), during the fast and 20 days
after  it;  decreased levels of D-dimmer and reduced homocys-
teine,  which translates in an improved coagulation proﬁle,
were  also observed. Three years later, in  a  similar study design,
the  same author measured inﬂammatory markers levels, such
as IL-6 and CRP, during Ramadan. The results demonstrated
a  decrease in the inﬂammatory response, since plasma levels
of  IL-6 and CRP were consistently reduced by fasting.43
Allard et al. assessed cellular stress in healthy individuals
subjected to IF for three weeks.44 Serum samples obtained
before  and after the intervention were added to cultures of
human  hepatoma cell line (HepG2). The effects on growth,
stress  resistance, and gene expression were observed. HepG2
cells  were then subjected to acute stress by treatment with
freshly  prepared hydrogen peroxide. The results demon-
strated  cell proliferation and increased stress resistance. This
study  also conﬁrmed previous reports of an increased expres-
sion  of the Sirt 1 gene after IF.  The results obtained showed
that  IF had a  signiﬁcantly greater cell-protective effect than
calorie  restriction.
Another study on healthy subjects appraised changes
in adipokine levels after the energetic oscillations caused
by  IF. After two weeks of intervention, subjects showed an
increase  in plasma adiponectin levels and increased insulin
sensitivity  in  muscle and fat tissue, which was conﬁrmed by
increased  lipolysis inhibition.3
Finally, Varady et al. presented a  revision of the impact of
IF  on the prevention of chronic diseases in  healthy human
and  animal models.45 Although most human results were
found  to  be inconclusive, they showed a  tendency to  improve
metabolic conditions (glycemia and blood lipids), which
would  probably reﬂect in cardiovascular risk reduction. The
lack  of signiﬁcance found in human studies is probably a
consequence of the short length of the interventions and of
the  absence of a  control group in most studies, reﬂecting the
need  for more  studies to  precisely determine the impacts of
this  intervention in humans.45
Although there are important differences in the strength
of  the results found, these ﬁndings in humans reﬂect the
beneﬁts  observed in animal models, and also show similar
underlying mechanisms, such as genetic modulation. Indeed,
the  described results motivated the investigation of IF and its
possible therapeutic effects in diseased individuals.
Protective  actions  of  intermittent  fasting  in  obese
individuals
IF for a period longer than a  few weeks is difﬁcult for most
individuals, since they tend to develop headaches, dizzi-
ness,  and irritability.40 Therefore, an alternative approach -
alternate-day  calorie restriction (ADCR) -  has been developed
to  promote patient compliance. In this approach, patients
have ad libitum and very-low-calorie diet on alternate days
(ranging  from 25% to  85% restriction). When tested on obese
individuals, this regimen showed higher adherence scores
than  others.22
Johnson et al. investigated the therapeutic properties of
ADCR  for two months in ten obese individuals with asthma.46
The study revealed that IF affected improvement in  the lipid
proﬁle,  systemic inﬂammatory status (reduced serum TNF-
levels),  and oxidative stress (decreased levels of reactive oxy-
gen  species). The authors concluded that ADCR induces mild
stress,  thereby causing cells to adapt by activating antioxidant
mechanisms; this would imply that IF may  be beneﬁcial in
other  disorders involving inﬂammation and oxidative stress,
such  as atherosclerotic heart disease.
The cardio-protective action of IF was examined by Varady
et  al.11 16  obese individuals underwent eight weeks of ADCR
25%,  i.e., they consumed 25%  of their baseline energy needs,
and  ad  libitum food on alternate days. The study results con-
ﬁrmed  the signiﬁcant cardio protective action of IF,  such as
weight  loss; reduction of fat tissue mass, blood pressure, and
heart  rate; and improvements in  lipid proﬁle, with decrease in
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total cholesterol and LDL-cholesterol levels, and an increase
in  HDL-cholesterol levels.
Conclusions
The development of cardiovascular disease, the leading cause
of  death worldwide, is  directly connected to lifestyle fac-
tors  causing metabolic disorders. Traditional approaches to
counter these risk factors have been proven ineffective in most
individuals.  However, IF has  recently been shown to  have a
positive  impact on cardiovascular health.
Few studies conducted hitherto have explored the effec-
tiveness of this intervention in metabolism regulation. The
studies  discussed in this paper have mostly been conducted
in  very small populations, on healthy individuals, and for short
periods,  which limits the strength of the results achieved. Fur-
ther  investigations are required to determine the  frequency
and/or duration of IF required to exert a positive effect on
metabolism and cardiovascular outcomes.
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